Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy.
An elevated erythrocyte arginase activity with a corresponding decrease in nitric oxide (NO) level has been implicated in the pathophysiology of sickle cell disease (SCD). Recent studies have shown that hydroxyurea (HU) increases the production of NO, which increases the soluble guanylate cyclase activity and fetal haemoglobin (HbF) synthesis. To study the effects of HU on the arginase and nitric oxide synthase (NOS) activities in SCD patients, we compared levels of arginase activity and NO metabolites in red blood cells and plasma, respectively, from 23 patients with SCD (HbSS) receiving HU therapy, with those of 12 SCD patients not receiving HU treatment. Patients on HU therapy showed significantly lower arginase activity than that of HbSS patients not on HU therapy (1.36+/-0.2 U/10(8) cells vs. 3.31+/-0.29 U/10(8) cells). NOS activity was higher in patients on HU therapy than in untreated patients (0.72+/-0.4 nmol/ml/min vs. 0.35+/-0.15 nmol/ml/min, P<0.05). Among the HU-treated patients, the decreased level of arginase activity correlated (r=0.71) with HbF level as well as the mean corpuscular haemoglobin content. These data suggest that one of the beneficial effects of HU in vivo may involve the regulation of arginase activity and a concomitant induction of NOS activity, which may lead to an increased production of NO. The outcome of this study may lead to the development of improved NO-based treatments for SCD.
Iyamu
Efemwonkiekie W
EW
Division of Hematology/Oncology, The Children's Mercy Hospital, Pediatric Research Center, Kansas City, MO 64108, USA. eiyamu@cmh.edu
Cecil
Renee
R
Parkin
Leslie
L
Woods
Gerald
G
Ohene-Frempong
Kwaku
K
Asakura
Toshio
T
D000293:Adolescent; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D000986:Antisickling Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001119:Arginase / Q000097:blood / Q000187:drug effects*; D002648:Child; D004912:Erythrocytes / Q000187:drug effects / Q000201:enzymology*; D005319:Fetal Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology* / Q000627:therapeutic use; D019001:Nitric Oxide Synthase / Q000097:blood / Q000187:drug effects
D000986:Antisickling Agents; D005319:Fetal Hemoglobin; D019001:Nitric Oxide Synthase; D001119:Arginase; D006918:Hydroxyurea